Clinical Trial Update: Study to Investigate the Efficacy of Elbasvir/Grazoprevir Fixed-Dose Combination for 8 Weeks in Treatment-Naïve, HCV GT1b-Infected Patients, With Non-severe Fibrosis [Phase 3]

View source ↗

Summary

Phase 3 trial of elbasvir/grazoprevir fixed-dose combo for 8 weeks in treatment-naïve patients with HCV genotype 1b and non-severe fibrosis has completed with r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• Elbasvir/Grazoprevir fixed-dose combination (elbasvir/grazoprevir)

Snippet

Sponsor: University Hospital, Clermont-Ferrand | Conditions: Chronic HCV Infection | Phase 3 | Status: COMPLETED | Results posted: 2020-09-07